Abstracts tagged "Myopathies"

Abstract Number: 1144 • ACR Convergence 2024
Autoantibody and Radiological Profiles as Prognostic Indicators in Idiopathic Inflammatory Myopathies: Insights into Mortality and Interstitial Lung Disease Development
cristiana sieiro santos¹, Miriam Retuerto², Laura Sierra², Jose Ordas Martínez³, Paula Pérez García², Pedro Baenas², Clara Moriano Morales² and Elvira Díez Álvarez⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, Leon, Spain
Background/Purpose: The idiopathic inflammatory myopathies (IIMs) constitute a diverse group of acquired muscle disorders, often involving multiple organs such as the skin, heart, and lungs.…
Abstract Number: 2059 • ACR Convergence 2024
The Rs35705950 Promoter Variant of Muc5b Is Associated with Usual Interstitial Pneumonia in Antisynthetase Syndrome
Daphne Rivero Gallegos¹, Mayra Mejía², Karol J. Nava-Quiroz², Heidegger N. Mateos-Toledo³, Héctor I. Rocha-González⁴, Juan C. Huerta-Cruz³, Espiridion Ramos-Martínez⁵, Gloria Pérez-Rubio³, Ingrid Fricke-Galindo³, Jorge Rojas-Serrano⁶ and Ramcés Falfán-Valencia³, ¹INER, Ciudad de México, Mexico State, Mexico, ²INER, Mexico, Distrito Federal, Mexico, ³INER, Mexico City, Distrito Federal, Mexico, ⁴Instituto Politècnico Nacional, Mexico City, Distrito Federal, Mexico, ⁵UNAM, Ciudad de Mexico, Distrito Federal, Mexico, ⁶National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico
Background/Purpose: Rs35705950 variant in the MUC5B gene promoter is a critical genetic risk factor in idiopathic pulmonary fibrosis (IPF). It has been associated with usual…
Abstract Number: 1146 • ACR Convergence 2024
Impact of COVID-19 on Myositis Testing Trends
Angel Kevin Garza-Elizondo¹, Rosa Icela Arvizu-Rivera², Pablo Gamez-Siller³, Daniela Alejandra Salcedo-Soto⁴, Jesus Cardenas-de la Garza⁵, Gisela Garcia-Arellano⁶, Miguel Angel Villarreal-Alarcon² and Dionicio Galarza-Delgado⁷, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ³Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, ⁴Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, ⁵Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ⁶Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, ⁷UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…
Abstract Number: 2066 • ACR Convergence 2024
Comparative Diagnostic Efficacy of Quantitative Measurement of Echo Intensity and Texture versus Qualitative Analysis of Ultrasound Images in Myositis
Takeshi Yoshida¹, Hiroki Yamazaki², Naoko Takamatsu², Yoshinori Taniguchi³, Taiki Nozaki⁴, masataka inoue⁵, Yoshitaka Kumon⁶, yuki matsumoto², Yuki Kanazawa², Masafumi Harada², Ichizo Nishino⁷, Jemima Albayda⁸ and Yuishin Izumi², ¹Chikamori Hospital, Kochi, Kochi, Japan, ²Tokushima University School of Medicine, Tokushima, Japan, ³Kochi University School of Medicine, kochi, Japan, ⁴keio University School of Medicine, Tokyo, Japan, ⁵Hyogo Medical University, Nishinomiya, Japan, ⁶Chikamori Hospital, Kochi, Japan, ⁷National Center of Neurology and Psychiatry, Tokyo, Japan, ⁸Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Recently, the role of imaging tests such as magnetic resonance imaging and ultrasound (US) in the diagnosis and classification of myositis has become increasingly…
Abstract Number: 1149 • ACR Convergence 2024
Cause-Specific Proportionate Mortality Trends in Idiopathic Inflammatory Myopathies
Ansaam Daoud¹, Muhammad Shamim², Loai Dweik³ and Haseeb Chaudhary⁴, ¹Case Western Reserve University/University Hospitals, Akron, OH, ²University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ³Cleveland Clinic Akron General Internal Medicine, Akron, OH, ⁴Case Western Reserve University, Westlake, OH
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are associated with increased morbidity, mortality, and economic health burden compared to the general population despite advancements in overall disease management.…
Abstract Number: 2067 • ACR Convergence 2024
Clinical and Laboratory Characterization of Overlap Connective Tissue Disease in Patients with Idiopathic Inflammatory Myopathies: Results from the MYOTReCSZ Cohort
karina santana¹, Jiram Torres Ruiz², Diana Gómez-Martin³, María José Ostos-prado⁴, Yatzil Reyna-Juárez⁴, Beatriz Alcalá-Carmona⁴, Mariana Arroyo⁵ and Nancy R Mejía-Domínguez⁴, ¹INCMNSZ, Ciudad de México, Distrito Federal, Mexico, ²INCMNSZ, Mexico, Federal District, Mexico, ³INCMNSZ, Mexico, Distrito Federal, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ⁵Angeles Interlomas, Mexico, Distrito Federal, Mexico
Background/Purpose: Idiopathic Inflammatory Myopathies (IIM) comprise systemic autoimmune dosorders which may occur in patients with other conective tissue diseases (CTD). The coexistence of IIM with…
Abstract Number: 1152 • ACR Convergence 2024
Nailfold Videocapillaroscopy Abnormalities in Different Autoimmune Inflammatory Myopathy Subsets
Thaisa Cotton¹, Valérie Leclair², Claudie Berger³, Yves Troyanov⁴, marie Hudson² and Geneviève Gyger², and Canadian Inflammatory Myopathy Study (CIMS), ¹Université de Montréal, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada
Background/Purpose: Nailfold videocapillaroscopy (NVC) alterations have mostly been described in autoimmune inflammatory myopathies (AIM) classified using Bohan and Peter criteria. The aim of this study…
Abstract Number: 2071 • ACR Convergence 2024
Self-Efficacy Contributes to Better Health Outcomes in Patients of Idiopathic Inflammatory Myopathies: Insights from the COVAD 3 Dataset
praggya yaadav¹, Maria Rosa Pellico², Anne-Marie Russell³, Aviya Lanis⁴, Elena Nikiphorou⁵, Ioannis Parodis⁶, Sreoshy Saha⁷, Manali Sarkar⁸, Jasmine Parihar⁹, Laura Andreoli¹⁰, Vikas Agarwal¹¹ and Latika Gupta¹², and COVAD Steering Committee, COVAD Study Group, ¹Maharashtra Institute of Medical Sciences and Research, Latur, Aurangabad, India, ²University of Milan, Milan, Italy, ³Birmingham Regional Interstitial Lung Disease Service, University Hospitals Birmingham NHS Trust and Faculty of Life Sciences, University of Exeter, Exeter, UK, Birmingham, United Kingdom, ⁴Seattle Children's Hospital, Seattle, WA, ⁵King's College London, London, United Kingdom, ⁶Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁷Mymensingh Medical College, Mymensingh, Bangladesh, ⁸MGM Medical College, Navi Mumbai, Maharashtra, India, ⁹All India Institute of Medical Science, New Delhi, Delhi, India, ¹⁰University of Brescia, Brescia, Italy, ¹¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹²Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom
Background/Purpose: Self-efficacy is crucial for chronic disease management. Given the increasing prevalence of chronic diseases, encouraging patients to actively manage their disease may be an…
Abstract Number: 1155 • ACR Convergence 2024
Stratification of Cancer Risk in Idiopathic Inflammatory Myopathies. Application of the IMACS Guidelines to Enhance Screening
Miriam Retuerto Guerrero¹, Clara Moriano², cristiana sieiro santos³ and elvira Diez álvarez⁴, ¹Complejo Asistencial Universitario de León, Leon, Spain, ²Hospital León, LEON, Spain, ³Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ⁴Complejo Asistencial Universitario de Leon, Leon
Background/Purpose: Idiopathic inflammatory myopathies (IIM) carry an elevated risk of cancer incidence. Recently published International Guidelines for IIM-associated cancer screening from the Myositis Assessment and…
Abstract Number: 2073 • ACR Convergence 2024
Ultrasound Findings of Activity in Patients with Inflammatory Myopathies and Clinical and Laboratory Comparison
Carina Soto-Fajardo¹, Alejandra Espinosa-Orantes², Alejandra Enríquez-Luna³, Fabian Carranza Enriquez⁴, Tabata Cano-Gamez³, Ana Mora-Rosas⁵, Rosa Elena Cervantes-Ramirez⁵, Karen Contreras-Castillo⁵, Jiram Torres Ruiz⁶, Diana Gómez-Martin⁷ and Carlos Pineda⁸, ¹Instituto Nacional de Rehabilitacion "Luis Guillermo Ibarra Ibarra", Mexico City, Mexico, ²Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Ciudad de México, Mexico, ³Instituto Nacional de Rehabilitacion, Mexico, Distrito Federal, Mexico, ⁴Instituto Nacional de Rehabilitación \"Luis Guillermo Ibarra Ibarra\", Ciudad de México, Mexico, ⁵Instituto Nacional de Rehabilitación "Luis Guillermo Ibarra Ibarra", Mexico, Distrito Federal, Mexico, ⁶INCMNSZ, Mexico, Federal District, Mexico, ⁷INCMNSZ, Mexico, Distrito Federal, Mexico, ⁸Instituto Nacional de Rehabilitacion, Mexico City, Distrito Federal, Mexico
Background/Purpose: Muscle ultrasound (MUS) is a non-invasive tool that may explore the extent of muscle abnormalities and contribute to early diagnosis and follow-up of patients…
Abstract Number: 1159 • ACR Convergence 2024
Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
Sangmee Bae¹, Francisca Bozan², Daphne Rivero Gallegos³, Giovanni Zanframundo⁴, Sara Faghihi-Kashani⁵, iazsmin Ventura⁶, Eduardo Dourado⁷, Aravinthan Loganathan⁸, Gianluca sambataro⁹, Akira Yoshida¹⁰, Francesco Bonella¹¹, Tamera J Corte¹², Tracy J Doyle¹³, david fiorentino¹⁴, Miguel Angel Gonzalez-Gay¹⁵, marie Hudson¹⁶, Masataka Kuwana¹⁷, Antonella Notarnicola¹⁸, Andrew Mammen¹⁹, Neil McHugh²⁰, Frederick Miller²¹, Carlomaurizio Montecucco²², Chester Oddis²³, Jorge Rojas-Serrano²⁴, Jens Schmidt²⁵, Carlo Scire²⁶, Albert Selva-O’Callaghan²⁷, Victoria Werth²⁸, Lorenzo Cavagna²⁹ and Rohit Aggarwal³⁰, ¹UCLA, Los Angeles, CA, ²Hospital Clinico Universidad de Chile, Santiago, Chile, ³INER, Ciudad de México, Mexico State, Mexico, ⁴Università di Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Milano, Italy, ⁵Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, San Francisco, CA, ⁶Section of Rheumatology, University of Chicago, Chicago, IL, ⁷Unidade Local de Saúde da Região de Aveiro, Aveiro, Portugal, ⁸RUH, Middle Park, Queensland, Australia, ⁹University of Catania, Catania, Italy, ¹⁰Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, ¹¹Center for interstitial and rare lung diseases, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany, ¹²Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia, ¹³Brigham and Women's Hospital, West Roxbury, MA, ¹⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA, ¹⁵University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain, ¹⁶McGill University, Montreal, QC, Canada, ¹⁷Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, Tokyo, Japan, ¹⁸Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ¹⁹NIH, Bethesda, MD, ²⁰University of Bath, Bath, United Kingdom, ²¹NIH, NIEHS, Chapel Hill, NC, ²²IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ²³Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²⁴National Institute of Respiratory Diseases, Ismael Cosío Villegas, Mexico City, Mexico, ²⁵University Medical Center Goettingen, Göttingen, Germany, ²⁶University of Milano Bicocca, Milan, Italy, ²⁷Internal Medicine Department, Universitat Autònoma de Barcelona, Barcelona, Spain, ²⁸University of Pennsylvania, Wynnewood, PA, ²⁹University of Pavia, Pavia, Italy, ³⁰Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: Anti-synthetase syndrome (ASSD) is a subset of idiopathic inflammatory myopathy characterized by autoantibodies directed against aminoacyl tRNA synthetases. Interstitial lung disease (ILD) can be…
Abstract Number: 2074 • ACR Convergence 2024
Experience on the Use of Obinutuzumab off Label in Patients with Refractory Idiopathic Inflammatory Myopathy
Ivana Ilic¹ and Galina Marder², ¹Northwell, Brooklyn, NY, ²Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY
Background/Purpose: Idiopathic inflammatory myopathy (IIM) is a rare multisystem inflammatory condition leading to significant disability. The management of IIM remains challenging. B cell targeting therapies are…
Abstract Number: 0319 • ACR Convergence 2024
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
Farbod Moghaddam¹, Mark Tarnopolsky², Valérie Leclair³, marie Hudson³, Ross Mitchell⁴, Katherine Buhler¹, Erin Hatcher⁵, Meifeng Zhang¹, Antoine Dufour¹, Luiz de Almeida¹, Marvin Fritzler⁶ and May Choi¹, ¹University of Calgary, Calgary, AB, Canada, ²McMaster University, Hamilton, ON, Canada, ³McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, Canada, ⁵McMaster University, Hamilton, Canada, ⁶Mitogen Diagnostics Corp, Calgary, AB, Canada
Background/Purpose: Sporadic inclusion body myositis (sIBM) is often challenging to diagnose because many patients have no known biomarkers (seronegative). Machine learning was applied to identify…
Abstract Number: 1160 • ACR Convergence 2024
Short Form-36 Psychometric Properties in Idiopathic Inflammatory Myopathies: Reliability, Validity and Responsiveness
shiri keret¹, Anushka Aggarwal², Maha Almackenzie³, Tanya Chandra⁴, Raisa Silva⁵, Eugenia Gkiaouraki⁶, Nantakarn Pongtarakulpanit⁷, shreya Sriram⁶, Chester Oddis⁷ and Rohit Aggarwal⁸, ¹Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ²Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, ³Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The quality of life, as measured by the Short Form-36 (SF-36), is reduced in patients with idiopathic inflammatory myopathies (IIM). Although endorsed by the…
Abstract Number: 2076 • ACR Convergence 2024
Comparing the Efficacy of Conventional Immunosuppression and Rituximab in Anti-SRP Myositis: Insights from a Tertiary Care Centre Experience
ABHILASHA ARVIND MANWATKAR¹, Ajith Sivadasan², adinair Vijakrishnan², John Antony Jude Prakash³, chandhu aS⁴, JOHN KUMAR DAS⁵, Meera S N², illiasul Ibad k² and JOHN MATHEW¹, ¹christian medical college, vellore, Tamil Nadu, India, ²Christian Medical College, vellore, ³Chritian Medical College, Vellore, ⁴CMC Vellore, Vellore, Tamil Nadu, India, ⁵Christian Medical College, Vellore, India
Background/Purpose: There is a relative scarcity of studies on the effective management of Anti-signal recognition particle (anti-SRP) myositis. Recent consensus on anti-SRP myositis shows that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.